Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis

BMC Cancer

Research Article

Garbiñe Sarriugarte¹  Nicolien T. van Ravesteyn²  Myriam Soto-Gordoa³  Arantzazu Arrospide⁴  Javier Mar⁵  Montserrat Rue⁶  Merce Comas⁷ 

[1] Breast Cancer Early Detection Programme, Public Health Division of Bizkaia, Basque Government, Alameda Rekalde 39, 48008, Bilbao, Bizkaia, Spain;Department of Public Health, Erasmus University Medical Center Rotterdam, Dr Molewaterplein 50, 3015, Rotterdam, GE, The Netherlands;Gipuzkoa AP-OSI Research Unit, Integrated Health Organization Alto Deba, Avda Navarra 16, 20500, Arrasate-Mondragón, Gipuzkoa, Spain;Gipuzkoa AP-OSI Research Unit, Integrated Health Organization Alto Deba, Avda Navarra 16, 20500, Arrasate-Mondragón, Gipuzkoa, Spain;Aging and Chronicity Health Services Research Group, BIODONOSTIA Research Institute, Paseo Dr Beguiristain s/n, 20014, Donostia, Gipuzkoa, Spain;REDISSEC (Red de Investigación en Servicios de Salud en Enfermedades Crónicas – Spanish Health Services Research on Chronic Patients Network), Bilbao, Bizkaia, Spain;Gipuzkoa AP-OSI Research Unit, Integrated Health Organization Alto Deba, Avda Navarra 16, 20500, Arrasate-Mondragón, Gipuzkoa, Spain;Aging and Chronicity Health Services Research Group, BIODONOSTIA Research Institute, Paseo Dr Beguiristain s/n, 20014, Donostia, Gipuzkoa, Spain;REDISSEC (Red de Investigación en Servicios de Salud en Enfermedades Crónicas – Spanish Health Services Research on Chronic Patients Network), Bilbao, Bizkaia, Spain;Health Management Service, Integrated Health Organization Alto Deba, Avda Navarra 16, 20500, Arrasate-Mondragón, Gipuzkoa, Spain;REDISSEC (Red de Investigación en Servicios de Salud en Enfermedades Crónicas – Spanish Health Services Research on Chronic Patients Network), Bilbao, Bizkaia, Spain;Basic Medical Sciences department, Biomedical Research Institute of Lleida, University of Lleida, Avda. Rovira Roure 80, 25198, Lleida, Spain;REDISSEC (Red de Investigación en Servicios de Salud en Enfermedades Crónicas – Spanish Health Services Research on Chronic Patients Network), Bilbao, Bizkaia, Spain;Evaluation and Epidemiology Department, Hospital del Mar – IMIM (Hospital del Mar Medical Research Institute), Passeig Maritim 25-29, 08003, Barcelona, Spain;

关键词: Breast cancer;    Screening;    Cost-effectiveness;    Budget impact analysis;    Simulation;    Modelling;    Evaluation;    Public health;   

DOI  :  10.1186/s12885-016-2386-y

 received in 2015-09-17, accepted in 2016-05-25,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundBreast cancer screening in the Basque Country has shown 20 % reduction of the number of BC deaths and an acceptable overdiagnosis level (4 % of screen detected BC). The aim of this study was to evaluate the breast cancer early detection programme in the Basque Country in terms of retrospective cost-effectiveness and budget impact from 1996 to 2011.MethodsA discrete event simulation model was built to reproduce the natural history of breast cancer (BC). We estimated for lifetime follow-up the total cost of BC (screening, diagnosis and treatment), as well as quality-adjusted life years (QALY), for women invited to participate in the evaluated programme during the 15-year period in the actual screening scenario and in a hypothetical unscreened scenario. An incremental cost-effectiveness ratio was calculated with the use of aggregated costs. Besides, annual costs were considered for budget impact analysis. Both population level and single-cohort analysis were performed. A probabilistic sensitivity analysis was applied to assess the impact of parameters uncertainty.ResultsThe actual screening programme involved a cost of 1,127 million euros and provided 6.7 million QALYs over the lifetime of the target population, resulting in a gain of 8,666 QALYs for an additional cost of 36.4 million euros, compared with the unscreened scenario. Thus, the incremental cost-effectiveness ratio was 4,214€/QALY. All the model runs in the probabilistic sensitivity analysis resulted in an incremental cost-effectiveness ratio lower than 10,000€/QALY. The screening programme involved an increase of the annual budget of the Basque Health Service by 5.2 million euros from year 2000 onwards.ConclusionsThe BC screening programme in the Basque Country proved to be cost-effective during the evaluated period and determined an affordable budget impact. These results confirm the epidemiological benefits related to the centralised screening system and support the continuation of the programme.

【 授权许可】

CC BY   
© The Author(s). 2016